1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-MM-016, FHCRC-2068.00, CELGENE-CC-5013-MM-016, NCT00179647
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCI 07-134, NCT00777881
|
|
3.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LENA-LMA-5, NCT01198054
|
|
4.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E3A06, E3A06, NCT01169337
|
|
5.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-DLC-001, NCT01197560
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-CLL-002, NCT00774345
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E2905, E2905, NCT00843882
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: LenaMain-Trial, NCT00891384
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 65 and ovr
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-CLL-008, Eudract #: 2008-003079-32, NCT00910910
|
|
10.
|
Phase: Phase III
Type: Health services research, Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-MDS-005, NCT01029262
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 60 to 75
Sponsor: Other
Protocol IDs: DSMM XIII, NCT01090089
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: EORTC-21081, EU-21020, EUDRACT-2009-011020-65, CELGENE-EORTC-21081, NCT01098656
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: RV-MM-EMN-441, NCT01091831
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EMN01, NCT01093196
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: NCI, NHLBI
Protocol IDs: 690, NCT01109004
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 60 to 80
Sponsor: Other
Protocol IDs: REMARC, NCT01122472
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 09 110 01, NCT01191060
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 10-106, NCT01208662
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: HOVON 95 MM, 2009-017903-28, EMN02, NCT01208766
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA204-004, 2010-020347-12, NCT01239797
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SINTRA-REV, 2009-013619-36, NCT01243476
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA204-006, 2010-022445-20, NCT01335399
|
|
23.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: RV-FOL-GELARC-0683C, 2011-002792-42, NCT01476787
|
|
24.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: 2081-113, NCT01530594
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EudraCT number: 2009-010956-93, NCT01554852
|
Mobile | Español
